EPIQ Systems, Inc. EPIQ has received an initial look from a private equity firm, according to dealReporter.
EPIQ Systems stated on September 18 that is its exploring strategic and financial alternatives. The company then rejected a $20 per share bid by P2 Capital, a 16.9 percent shareholder who wanted to take the firm private. The company said that the P2 bid does not unlock long-term value.
EPIQ has also adopted a poison pill following activist investor St. Denis J. Villere & Co showing a 16.22 percent stake in September.
EPIQ has previously retained bankers at Credit Suisse to advise the company on its potential options.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.